Psoriasis, a chronic inflammatory skin disease is associated with heightened immune activation, accelerated cardiovascular (CV) risk as well as increased acute coronary syndromes, most evident in young adults (Gelfand et al., 2006). This inflammatory skin disease confers an independent risk for myocardial infarction (MI) beyond traditional CV risk factors (Mehta et al., 2010) and on average leads to a decreased lifespan of five years (Gelfand et al., 2006). One explanation is the susceptibility of psoriasis patients to develop unstable, lipid-rich non-calcified coronary plaques (NCB) that are vulnerable to rupture (Lerman et al., 2017). Murine studies of atherosclerosis and rheumatoid arthritis have identified myelopoiesis to be associated with progression of atherosclerosis (Dragoljevic et al., 2018). Interestingly, in psoriasis, we have shown that 18-fluorodeoxyglucose (FDG) uptake in the bone marrow, a surrogate marker of bone marrow granulopoiesis is upregulated